These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 3663814)

  • 21. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials.
    Tamura RN; Huang X
    Clin Trials; 2007; 4(4):309-17. PubMed ID: 17848492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple-arm superiority and non-inferiority designs with various endpoints.
    Chang M
    Pharm Stat; 2007; 6(1):43-52. PubMed ID: 17323311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interim analysis of continuous long-term endpoints in clinical trials with longitudinal outcomes.
    Galbraith S; Marschner IC
    Stat Med; 2003 Jun; 22(11):1787-805. PubMed ID: 12754715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Weighted multiple testing correction for correlated tests.
    Xie C
    Stat Med; 2012 Feb; 31(4):341-52. PubMed ID: 22114000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and analysis of group sequential clinical trials with multiple primary endpoints.
    Kosorok MR; Yuanjun S; DeMets DL
    Biometrics; 2004 Mar; 60(1):134-45. PubMed ID: 15032783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A clinician's guide for conducting randomized trials in individual patients.
    Guyatt G; Sackett D; Adachi J; Roberts R; Chong J; Rosenbloom D; Keller J
    CMAJ; 1988 Sep; 139(6):497-503. PubMed ID: 3409138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomization as a basis for inference in noninferiority trials.
    Wiens BL
    Pharm Stat; 2006; 5(4):265-71. PubMed ID: 17128425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment allocation for nonlinear models in clinical trials: the logistic model.
    Begg CB; Kalish LA
    Biometrics; 1984 Jun; 40(2):409-20. PubMed ID: 6487725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monitoring pairwise comparisons in multi-armed clinical trials.
    Follmann DA; Proschan MA; Geller NL
    Biometrics; 1994 Jun; 50(2):325-36. PubMed ID: 8068834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A power study of a sequential method of p-value adjustment for correlated continuous endpoints.
    Arani RB; Chen JJ
    J Biopharm Stat; 1998 Nov; 8(4):585-98. PubMed ID: 9855036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Partition testing in dose-response studies with multiple endpoints.
    Liu Y; Hsu J; Ruberg S
    Pharm Stat; 2007; 6(3):181-92. PubMed ID: 17654696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prentice's approach and the meta-analytic paradigm: a reflection on the role of statistics in the evaluation of surrogate endpoints.
    Alonso A; Molenberghs G; Burzykowski T; Renard D; Geys H; Shkedy Z; Tibaldi F; Abrahantes JC; Buyse M
    Biometrics; 2004 Sep; 60(3):724-8. PubMed ID: 15339295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Double-blind clinical trial of domiodol vs S-carboxymethylcysteine in chronic obstructive lung disease.
    Casali L; Rampulla C; Rossi A
    Int J Clin Pharmacol Ther Toxicol; 1982 Nov; 20(11):554-7. PubMed ID: 6757153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of onset of bronchodilating effect by interruption of the air flow method.
    Lulling J; Delwiche JP; Prignot J
    Eur J Respir Dis; 1980 Apr; 61(2):108-12. PubMed ID: 7002572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis strategies for adaptive designs with multiple endpoints.
    Chang M; Chow SC
    J Biopharm Stat; 2007; 17(6):1189-200. PubMed ID: 18027225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Challenge of multiple co-primary endpoints: a new approach.
    Chuang-Stein C; Stryszak P; Dmitrienko A; Offen W
    Stat Med; 2007 Mar; 26(6):1181-92. PubMed ID: 16927251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Power and sample size when multiple endpoints are considered.
    Senn S; Bretz F
    Pharm Stat; 2007; 6(3):161-70. PubMed ID: 17674404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.
    Sertdemir Y; Burgut R
    Contemp Clin Trials; 2009 Jan; 30(1):8-12. PubMed ID: 18809512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiplicity and flexibility in clinical trials.
    Brannath W; Koenig F; Bauer P
    Pharm Stat; 2007; 6(3):205-16. PubMed ID: 17674349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A sequential test for comparing two infection rates in a randomized clinical trial, and incorporation of data accumulated after stopping.
    Samuel-Cahn E; Wax Y
    Biometrics; 1986 Mar; 42(1):90-108. PubMed ID: 3719066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.